secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2025-01-21T23:59:59+00:00
Accession:  0001493152-25-002928
Event type: leadership
Sentiment:  neutral
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics appoints CFO Janet Huffman as interim CEO; provides ONP-002 Phase II timeline
--------------------------------------------------------------------------------

- CFO Janet Huffman named interim CEO, retaining CFO role; board expresses confidence in her leadership.
- Company raised $4M in September 2024; progress includes improved ONP-002 formulation and device prototyping.
- Phase II trial in Australia: first patient dosing targeted by end of Q1 2025 or early Q2 2025.
- IND package for U.S. Phase IIb clinical trial targeted for Q3 2025.
- Spray-dry campaign completed to ensure sufficient drug-device units for upcoming trials.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315225002928/0001493152-25-002928-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315225002928/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-002928

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer